Drug Details
General Information of the Drug (ID: DR4313) | ||||
---|---|---|---|---|
Name |
Ertugliflozin
|
|||
Synonyms |
Ertugliflozin; 1210344-57-2; PF-04971729; Steglatro; PF04971729; UNII-6C282481IP; 1,6-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-5-C-(hydroxymethyl)-beta-L-idopyranose; CHEMBL1770248; 1210344-57-2 (free base); 6C282481IP; (1S,2S,3S,4R,5S)-5-(4-Chloro-3-(4-ethoxybenzyl)phenyl)-1-hydroxymethyl-6,8-dioxabicyclo(3.2.1)octane-2,3,4-triol; (1S,2S,3S,4R,5S)-5-(4-chloro-3-(4-ethoxybenzyl)phenyl)-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol; (1S,2S,3S,4R,5S)-5-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol; PF 04971729; Ertugliflozin [USAN:INN]; (1s,2s,3s,4r,5s)-5-[4-chloro-3-(4-ethoxybenzyl)phenyl]-1-hydroxymethyl-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol; MK-8835; Tube108; Ertugliflozin (USAN/INN); PF 04971729-00; PF-04971729-00; cc-212; SCHEMBL181047; GTPL8376; PF-04971729;Ertugliflozin; DTXSID40153120; EX-A407; AMY32613; ABP000359; BDBM50342885; MFCD21609259; s5413; ZINC68197809; AKOS025404928; CCG-269087; CS-0976; DB11827; SB11082; 5-(4-chloro-3-(4-ethoxybenzyl)phenyl)-1-hydroxymethyl-6,8-dioxabicyclo(3.2.1)octane-2,3,4-triol; AC-29007; AS-35204; beta-L-Idopyranose, 1,6-anhydro-1-C-(4-chloro-3-((4-ethoxyphenyl)methyl)phenyl)-5-C-(hydroxymethyl)-; HY-15461; Y0303; D10313; W-5850; J-504029; PF-04971729/PF04971729/; Q27077223; (1S,2S,3S,4R,5S)-5-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-1-hydroxymethyl-6,8-dioxa-bicyclo[3.2.1]octane-2,3,4-triol; (1S,2S,3S,4R,5S)-5-[4-Chloro-3-(4-ethoxybenzyl)phenyl]-1-(hydroxymethyl)-6,8-dioxa-bicyclo[3.2.1]octane-2,3,4-triol; (1S,5S)-1-(Hydroxymethyl)-5-[3-(4-ethoxybenzyl)-4-chlorophenyl]-6,8-dioxabicyclo[3.2.1]octane-2beta,3alpha,4beta-triol
Click to Show/Hide
|
|||
Molecular Type |
Small molecule
|
|||
Disease | Type 2 diabetes mellitus [ICD-11: 5A11] | Approved | [1] | |
Structure |
![]() |
Click to Download Mol2D MOL |
||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
Formula |
C22H25ClO7
|
|||
PubChem CID | ||||
Canonical SMILES |
CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C34C(C(C(C(O3)(CO4)CO)O)O)O)Cl
|
|||
InChI |
1S/C22H25ClO7/c1-2-28-16-6-3-13(4-7-16)9-14-10-15(5-8-17(14)23)22-20(27)18(25)19(26)21(11-24,30-22)12-29-22/h3-8,10,18-20,24-27H,2,9,11-12H2,1H3/t18-,19-,20+,21-,22-/m0/s1
|
|||
InChIKey |
MCIACXAZCBVDEE-CUUWFGFTSA-N
|
|||
CAS Number |
CAS 1210344-57-2
|
|||
TTD Drug ID | ||||
DrugBank ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
Metformin | Galega officinalis | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) |
Combination Info
![]() |
|||||
In-vivo Model | Clinical trial | |||||
Experimental
Result(s) |
The fixed-dose combination of ertugliflozin with metformin is an effective combination that is conveniently administered and may improve medication adherence and persistence. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Sodium/glucose cotransporter 2 (SGLT2) | Molecule Info | [3] | |
Reactome | Hexose transport | Click to Show/Hide | ||
2 | Na+-dependent glucose transporters | |||
3 | Inositol transporters | |||
WikiPathways | NRF2 pathway | Click to Show/Hide | ||
2 | Nuclear Receptors Meta-Pathway | |||
3 | Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds |
